

VOLUME 38 1991

SUBJECT INDEX

- AB mice, 471
 Acetylcholine, 115, 227, 501, 723, 731, 921
 Acetylcholinesterase, 93
 Acetyltransferase, 813
 ACh release, 441
Acomys cahirinus, 913
 Acoustic startle reflex, 769
 Activity, 485
 Acute dependence, 711
 Adenosine receptors, 1
 Adenosine uptake sites, 1
 Adenylate cyclase, 555
 Adrenalectomy, 593
 Adrenaline, 13, 299
 α_1 -Adrenoceptor, 353
 α -2-Adrenoceptor, 287
 Affective disorders, 227, 695
 Afterdischarge, 669
 Aggression, 485, 587, 639
 Aggressiveness, 471
 Aging, 861
 Alcohol-ethyl, 639
 Alcohol intake, 881
 Alpha-1 adrenergic receptors, 905
 Alprenolol, 353
 Alzheimer's disease, 141, 921
 Ambient temperature, 339
 2-Amino-1,2-dihydronaphthalene (ADN), 581
 2-Aminoindan, 581
 2-Aminotetralin (AT), 581
 Ambulatory activity, 781
 Amphetamine, 365, 375, 467, 927
 (+)-Amphetamine, 581
 d-Amphetamine, 417, 633
 Amygdaloid kindling, 669
 Analgesia, 155, 185, 401, 485, 561, 681, 795, 853
 Analgesic, 21
 Analgesic agents, 909
 Angiotensin II, 913
 Angiotensin II-induced drinking, 837
 Animal model, 141, 889
 Animal model of depression, 191
 Anorexia, 459, 905
 Antagonism, 479
 Anterograde amnesia, 651
 Antidepressants, 621
 Antihypertensive agents—adverse side-effects, 55
 Antinociception, 287, 753
 Antiopiate, 273
 Antiseizure efficacy, 665
 Anxiety, 63, 99, 519, 651, 889
 Anxiety drugs, 769
 Anxiety reduction after ejaculation, 807
 Anxiolytics, 43
 Apomorphine, 309, 321, 463, 869, 917
 Appetitive conditioning, 109
 Approach behavior, 191
 Arousal, 333, 723
 Arrhythmias, 601
 Arterial blood pressure, 913
 ASU 1-7 eel calcitonin, 561
 Atipamezole, 287
 Atmospheric pressure, 639
 Atropine, 747
 Autoradiography, 621
 Aversive stimuli, 401, 795
 Avoidance behavior, 191

 BC-264, 545
 BC (3016), 401
 BDZ receptor ligands, 13
 Behavior, 155, 539, 639, 817
 Behavior genetics, 893
 Behavioral deficit, 441, 795
 Behavioral economics, 715
 Behavioral pharmacology, 527
 Behavioral teratology, 739
 Behavioral toxicology, 527
 Benoxathian, 905
 Benzodiazepine and fixed interval behavior, 823
 Benzodiazepine and spontaneous activity, 823
 Benzodiazepine inverse agonist, 763
 Benzodiazepine receptor, 99
 Benzodiazepines, 43, 781, 889
 Beta-funaltrexamine, 49
 Bicuculline, 593
 Bilateral transection, 931
 Binding, 231
 Blink rate, 869
 Blood-brain barrier, 155, 327
 Blood ethanol concentration, 699
 Blood pressure, 55, 601, 843
 Body temperature, 29, 253
 Body weight, 495
 Brain ethanol, 29
 Brain injury, 327
 Brain lesions, 869
 Brain serotonin, 775
 Brain-stimulation reward, 645
 Bright light, 227, 695
 2-Bromolisuride, 321
 BUBU, 155
 Burying behavior, 63, 371, 807
 Buspirone, 299, 611

 C57BL/6J mice, 177, 897
 Caffeine, 333, 513
 Calcium channel blocking agents, 55
 Canine narcolepsy, 1
 Carbachol, 115
 Carbamate, 527
 Carbohydrate intake, 177
 β -Carbolines, 519
 5-Carboxamidotryptamine, 459
 Cardiotoxicity, 601
 Cardiovascular, 333
 Cardiovascular function, 843
 Cat, 287
 Catalepsy, 105, 673, 875
 Catecholamines, 345, 677
 Catecholamines, plasma, 843
 Cathinone, 7
 Caudate nuclei, 739
 CCK, 479
 CCK antagonists, 207
 CCK-B receptors, 545
 Cellular tolerance, 29
 Central nervous system, 147
 Cerebrospinal fluid, 677
 CGS 10746B, 7
 Chicken, 247
 Chlordiazepoxide, 13, 43, 299, 375, 433
p-Chloroamphetamine, 135
 Choline, 723
 Choline acetyltransferase, 861
 Cholinergic, 227, 243, 501
 Cholinergic muscarinic binding, 861
 Cholinergic supersensitivity, 105
 Cholinergic systems, 527
 Cholinesterase inhibitor, 549
 Chronic, 495
 Chronic administration, 611
 Chronic opioid agonists and antagonists, 485
 Chronic variable stress, 125
 Circadian rhythms, 253
 Cigarette smoking, 333, 417
 Circling training, 739
 Climbing, 463
 Clonidine, 177
 Clorgyline, 677
 Cocaine, 267, 287, 353, 411, 467, 601, 893, 897, 927
 Coffee, 333
 Cognition, 169
 Colchicine, 141
 Cold challenge, 253
 Cold exposure, 837
 Cold-induced hypertension, 837
 Cold stress, 813
 Color discrimination, 55, 77
 Compensatory tracking, 527
 Computed tomography, 327
 Conditioned avoidance responses, 705
 Conditioned place preference, 7, 539
 Conditioned position responding, 77
 Conditioned suppression, 309
 Conditioned taste aversion, 267, 375, 479
 Conditioning, 375
 Consolidation, 651
 Corticosterone, 13, 299
 Cross-dependence, 433
 Cross-tolerance, 195, 427, 433
 CSF, 677
 CY 208-243, 259
 Cyclo(His-Pro), 359, 365
 d-Cycloserine, 665

 D₁, 243
 D₂, 243
 D₂ agonist, 147
 D1 receptor, 215, 259
 D2 receptor, 215
 DAGO, 155, 185
 Defeat, 485
 Delayed matching-to-sample, 77
 Delta and mu opioid receptors, 185
 Delta opioid agonist, 155
 Dependence, 433
 Depression, 315, 695
 Desipramine, 621
 Dexfenfluramine, 495, 775
 5,7-DHT, 807
 Diazepam, 63, 389, 471, 651
 Diet selection, 495

5,7-Dihydroxytryptamine, 447
 Discriminative stimulus, 407
 Displacement activities, 889
 Dispositional tolerance, 823
 Diurnal activity, 633
 Dizocilpine, 673
 DMCM, 13, 99
 DOCA-salt hypertension, 55
 DOI, 353
 Domestic fowl, 49, 587
 Dominance, 587
 Dopamine, 7, 69, 147, 215, 505, 539, 705, 789, 869, 917
 Dopamine antagonist, 321
 Dopamine D-2 receptors, 131
 Dopamine receptors, 829
 Dopamine sensitivity, 105
 Dorsal raphe nucleus, 223
 Dose-effect, 141
 DPDPE, 185
 Drinking, 253, 459, 913
 Drug dependence, 389
 Drug discrimination, 7, 99, 211, 407, 519, 539, 581, 763
 Drug effects, 77
 Drug regimen, 927
 Drug seeking, 389
 DSP4, 807

 Early exposure, 575
 ED₅₀, 673
 EEG, 293
 Ejaculation, 371
 Eltopazine (DU 28853), 447, 759
 Endorphin, 909
 β-Endorphin, 795
 Enkephalinase inhibitor, 21
 Enkephalins, 155
 Epilepsy, 163
 Epileptic spiking, 327
 Escape deficit, 125
 Eseroline, 747
 Ethanol, 29, 293, 389, 427, 433, 639, 665, 699, 763
 Ethanol initiation, 575
 Ethanol reinforcement, 575
 Ethopharmacology, 889
 Ethyl-beta-carboline-3-carboxylate, 63
 (+)-α-Ethylphenethylamine, 581
 Etorphine, 475
 Evaporative water loss, 339
 Experience of defeat, 315
 Exploration, 759

 Fat, 681
 Feed restriction, 587
 Feeding, 379, 495
 Fenfluramine, 365
 Fentanyl, 475
 FG 7142, 99, 519
 Fimbria fornix, 931
 Fixed ratio, 897
 Fixed-ratio (FR) liquid-reinforced behavior, 699
 Fixed-ratio responding, 747
 Fixed-ratio schedule, 411
 Flumazenil, 13
 2-(Fluorohydroxyphenyl)ethylamines, 131
 Fluoxetine, 495
 Flurazepam, 659
 Flurazepam, behavioral tolerance, 823
 Flurazepam elimination half-life, 823
 Flurazepam pharmacokinetics, rat, 823

 Food adaptation, 85
 Food intake, 223, 235, 359, 379, 417, 605, 775
 Footshock, 69
 Foot shock-induced analgesia, 561
 Formalin test, 247
 Forskolin, 753
 Frontal cortex, 93, 723
 FSL and FRL rats, 105

 GABA, 385, 659, 781, 801
 GABA antagonist (RU 5135), 327
 GABA_A receptor, 235
 GABA receptors, 829
 Gap inhibition, 769
 Gender differences, 253
 Genetic obesity, 177
 Ginkgo biloba, 109
 Glutamate, 385
 G-proteins, 1

 Halazepam dependence, 561
 Halazepam metabolism, 561
 Halazepam pharmacokinetics, 561
 Haloperidol, 471, 633, 645, 739, 869, 875
 Hamster, 711
 HDL-C, 813
 Head-twitch, 353
 Heart rate, 339, 843
 Heat challenge, 253
 Hematocrit, 913
 Hematuria, 689
 Hexobarbital, 471
 5-HIAA, 677
 Hippocampus, 93, 621, 705, 723, 801, 861
 Hot-plate, 185
 HPLC-EC, 135
 5-HT_{1A}, 691
 5-HT₂, 691
 5-HT agonists, 495
 5-HT behavioral syndrome, 555
 5-HT receptors, 201
 5-HT₁-like receptors, 459
 5-HT₁ receptors, 447
 5-HT_{1A} activity, 407
 5-HT_{1A} receptor, 353, 555
 5-HT_{1A} receptor agonist, 441
 5-HT₂ receptor, 353
 5-HT₃ receptor antagonist, 169
 5-HTP, 201
 Human, 417
 Hunger, 379
 HVA, 677
 6-Hydroxydopamine, 215
 5-Hydroxytryptamine, 459
 5-Hydroxytryptamine (5-HT) or serotonin, 191
 5-Hydroxytryptophan (5-HTP), 191
 Hyperalgesia, 247
 Hyperbaric, 639
 Hyperbaric pressure, 219
 Hyperthermia, 339
 Hypertonic NaCl, 913
 Hypothalamus, 379
 Hypothermia, 235, 339, 651

 ICI-154,129, 485
 ICS 205-930, 353, 605
 Imipramine, 93, 125, 407, 621
 Impotence, 917
 In vitro binding, 155, 621
 In vivo binding, 155, 621
 Incremental repeated acquisition, 77

 Individual differences, 467
 Indole-2-carboxylic acid, 665
 Inhalation, 699
 Insecticide, 235
 Insulin, 533
 Intracerebroventricular, 185
 Intracerebroventricular infusion, 379
 Intranigral infusion, 617
 Intravenous administration, 155
 Inverse agonist, 99, 519
 Iodoaminoindan, 135
p-Iodoamphetamine, 135
 3-Isobutyl-1-methylxanthine, 753
 Isoproterenol HCl, 913

 Jaw-opening reflex, 287

 Kainic acid, 689
 Kappa receptors, 401
 Ketamine, 211, 869
 Ketanserin, 605
 Kindling, 163

 L-365,260, 207
 Latent inhibition, 309
 Lateral ventricle, 705
 LD₅₀, 673
 Learned helplessness, 93
 Learned tolerance, 29
 Learning, 77, 231, 651
 Learning and memory, 731
 Lecithin:cholesterol, 813
 Lethality, 339, 673, 893
 Lever press, 109
 Levorphanol, 485
 LHRH, 705
 Licking, 463
 Lindane, 235
 Lisuride, 321
 Lithium, 93, 375, 533
 Locomotion, 155, 441
 Locomotor activity, 265, 321, 385, 467, 723, 829, 875
 Locomotor/exploratory activity, 817
 Locus coeruleus, 621
 Long latency event-related potentials, 789
 Long-term potentiation, 163

 Macronutrient selection, 177
 Male and female rats, 795
 Male sexual behavior, 201
 MAOI, 677
 Marble burying, 63
 Marmoset, 147, 169
 Maze, 759
 McN-A-343, 115
 MDMA, 345, 539
 Meal-feeding, 177
 Mechanisms of anesthesia, 639
 Mechanisms of intoxication, 639
 Medetomidine, 287
 Median raphe nucleus, 223
 Memory, 77, 109, 141, 243, 651
 Memory search, 281
 5-MeODMT, 201
 Metabolic rate, 339
 Metabolism, 345
 Metaphit, 231
 Methohexital, 411
 N-Methyl-D-aspartate, 673
 5,6-Methylenedioxy-2-aminoindan (MDAI), 581
 Methylenedioxyamphetamines, 505

- α-Methylepine, 345
- N'-Methylnicotinium iodide, 843
- Methysergide, 605
- Metoclopramide, 917
- MHPG, 677
- Mice, 109, 485, 593, 639, 763, 817
- Microdialysis, 723
- Microtubule, 141
- Midazolam, 611
- MK-329, 207
- MK-801, 163, 211, 231, 665, 673
- M. nemestrina*, 677
- Monkeys, 77, 677, 869
- Morphinan, 401
- Morphine, 37, 49, 77, 185, 195, 247, 273, 673, 681, 711, 753, 817, 853
- Morphine dependence, 479
- Morris water maze, 651, 931
- Mortality, 689
- Motivation, 77, 417
- Motor activity, 339, 471, 633
- Motor behavior, 55, 259
- Motor execution, 781
- Mouse, 259
- MPTP, 147, 869
- Mu, delta, kappa opioids, 485
- Multiple FR-TO schedule, 549
- Mu opioid agonist, 155
- Mu receptors, 401
- Muscarinic, 227, 243
- Muscarinic receptors, 695
- Muscarinic subtypes, 115
- Mus musculus*, 177
- Myoclonus, 235
- N. accumbens, 705
- Naloxone, 37, 43, 85, 247, 265, 371, 711, 747
- Naloxone hypophagia, 605
- Naltrexone, 485, 775, 853
- Naltrindole, 49, 185
- NAN-190, 407
- Narcotic antagonists, 247
- Narcotic drugs, 247
- Neurotoxicity, 505
- Neurokinin receptors, 223
- Neurokinins, 223
- Neuroleptics, 645
- Neuromodulation, 365
- Neuropeptide Y, 379
- Neuropeptide Y₁₋₂₇, 379
- Neurotensin, 463, 569
- Neurotoxicity, 135, 345, 505, 539
- Neurotoxin, 689
- NH₂-senktide, 881
- Nicotine, 281, 333, 501, 875, 921
- (+)-Nicotine, 843
- (-)-Nicotine, 843
- Nimodipine, 665
- Nitrazepam, 265
- NMDA, 385
- NMDA receptor, 665
- NMDA receptor antagonist, 163
- Nociception, 49, 247, 287, 401
- Nondeprived subjects, 223
- Nonhuman primates, 677, 889
- Nonhuman primates—baboons, 55
- Noradrenaline, 13, 299, 807
- α-Noradrenergic, 177
- Nor-binaltorphimine, 49
- Norepinephrine, 69
- Novel object, 759
- Novelty, 467
- Nucleus accumbens, 829
- Nucleus basalis magnocellularis, 731
- Obesity, 533
- Object discrimination reversal, 169
- ob/ob*, 177
- Obsessive-compulsive disorder, 63
- Occasional smokers, 281
- Offensive aggression, 447
- 8-OH-DPAT, 407
- Ondansetron, 169
- Ontogeny of ingestion, 207
- Open field, 759
- Operant behavior, 77, 195
- Operant conditioning, 141, 739
- Operant performance, 549
- Opiate, 49, 247, 475, 673, 909
- Opiates and drinking, 85
- Opiates and feeding, 85
- Opioid, 247, 673
- Opioid antagonist, 185, 801
- Opioid peptides, 195, 775, 801
- Opioid receptors, 49, 155, 195, 853
- Oral dyskinesia, 215
- Oral movements, 617
- Org2766, 931
- Organophosphate, 527
- Osmotic minipump, 677
- Oxotremorine-M, 115
- Oxytocin, 273
- Pain, 49, 247
- Palatability, 375
- Pancreas, 909
- Paralytic effects, 475
- Paraventricular nucleus, 905
- Parkinson's disease, 147
- Passive avoidance, 231, 931
- PCP, 231
- PCPA, 253
- Penile erection, 131
- Pentobarbital, 427
- Pentylentetrazol, 471
- Peptides, 379
- Perforant path, 801
- Performance, 417
- Peripheral benzodiazepine, 235
- Peripheral serotonergic mechanisms, 459
- Pertussis toxin, 561, 853
- Phencyclidine, 211
- Phenoxybenzamine, 689
- Phenylpropanolamine, 905
- PHNO, 869
- Phosphoinositide turnover, 861
- Physostigmine, 115
- Picrotoxin, 235
- Pigeon, 407, 611
- Piloerection, 339
- Pirenzepine, 115
- Place conditioning, 513, 645
- Plasma renin activity, 837
- Plasma β-endorphin, 219
- Polyethylene glycol, 913
- Position discrimination, 77
- Postsynaptic serotonin receptors, 191
- Power spectra, 293
- Precipitated withdrawal, 479
- Preference test, 37
- Prefrontal cortex, 645
- Preoptic area, 385
- Presynaptic receptor, 441
- Principal Component Analysis (PCA), 817
- Progressive ratio, 77
- Prolyl-leucyl-glycinamide, 273
- Psychopharmacology, 375
- Psychosis, 927
- PTZ, 99
- Pyridostigmine, 549
- Quantitative autoradiography, 447
- Quinpirole, 309
- Radial-arm maze, 243
- Rapid, 427
- Rat, 7, 13, 37, 43, 93, 99, 201, 253, 267, 299, 309, 321, 427, 447, 467, 519, 533, 539, 545, 575, 617, 669, 685, 699, 731, 769, 893, 921, 927
- Receptor binding, 691
- Receptor interactions, 829
- Receptor occupancy, 155
- Receptors, 227, 501
- Receptor turnover, 691
- Recovery, 931
- Reinforcement, 715
- Renin-angiotensin system, 837
- Renovascular hypertension, 55
- Repeated ECS, 691
- Reserpine, 259
- Resident-intruder, 447
- Residential laboratory, 417
- Restraint, 185
- Retention, 651
- Rhesus monkeys, 527
- Ritanserin, 605
- Ro 5-4864, 235
- Ro15-1788, 433
- Ro 15-4513, 763
- Ro 20-1724, 753
- Rodents, 147
- Rolipram, 753
- Rotation, 659
- Route of administration, 267, 601
- RU 24969, 495
- Saccharin, 681
- Saccharin concentrations, 37
- Salivation, 339
- Satiety mechanism, 379
- SCH 32615, 21
- Schedule-controlled behavior, 611, 747
- Schedule-induced polydipsia, 85
- Scopolamine, 115, 243, 467, 723
- Scratching, 889
- Scuba divers, 219
- Seasonal affective disorder, 227
- Second-order schedule, 411
- Sedation, 651
- Seizures, 235, 593
- Self-administration, 411, 897
- Self-stimulation, 645, 699
- Senktide, 223, 617
- Sensitization, 467
- Sensorimotor reactivity, 769
- Sensory contact model, 315
- Septide, 617
- Serotonergic supersensitivity, 447
- Serotonin, 69, 135, 365, 459, 505, 539, 731, 789, 807
- Serotonin agonist, 321, 459
- Serotonin analogs, 459
- Serotonin antagonists, 459
- Serotonin depletion, 253
- Serotonin receptors, 459
- Serotonin receptor subtypes, 605
- Sex, 533

Sexual behavior, 115, 273, 781
Shock stress, 93
Shuttle-box, 125
Signalled punishment, 43
SKF 38393, 215, 309
Skin temperature, 339
Sleep, 545
Sleep-wake cycle, 293
Smoking, 715
Sniffing, 463
Social attraction, 759
Social behavior, 389, 417
Social conflict, 485
Social dominance, 389
Social isolation, 389
Spatial learning, 931
Spiny mouse, 913
Spiperone, 215
Spontaneous alternation, 441
Spontaneous motor activity, 705
Squirrel monkey, 411, 633
Stereotypy, 105, 463
Stimulant, 339, 581
Stimulus properties of drugs, 99, 519, 539
Strain, 69
Stress, 185, 299, 501
Stretching and yawning, 131
Striatum, 93, 705, 723
Structure-activity relationships, 505
Subarachnoid catheterization, 685
Subjective effects, 417
Subjective ratings, 281
Submissive male, 315
Subsensitivity, 659
Substantia innominata, 385
Substantia nigra, 617
Substantia nigra pars reticulata, 659
Sucrose, 681
Sudden death, 601
Sulpiride, 533, 869
Supersensitivity, 853
Substitutability, 715
Synaptosomes, 505
Tachykinin analogues, 617
Tachykinins, 881
Tail-flick, 185, 681
Tardive dyskinesia, 617
Taste aversion, 513
Taste reactivity test, 375
Telemetry, 339
Temperature, 105
Temperature regulation, 235
Temporal response differentiation, 77
Test battery, 77
Test/treatment interaction, 817
THBC, 519
Theory of depression, 191
Thiazide diuretics, 55
THIP, 659
Thyrotropin-releasing hormone, 359
Time-course, 747
Time perception, 77
Tobacco, 921
Tolerance, 265, 427, 433, 467, 485, 699, 843
Tooth pulp, 287
Toxicity, 893
Toxicokinetics, 235
TRH, 669
Tritiated probe, 155
Tryptophan, 587
Tyrosine-prolyl-leucyl-glycinamide, 273
U-50,488, 485
Ultrasonic motion detector, 633
Upregulation, 853
Verapamil, 55
Vitamin A, 739
Voltage-sensitive calcium channels, 665
Water deprivation, 913
Water intake, 223, 379, 913
Wet dog shakes, 801
Withdrawal, 485, 711
Withdrawal signs, 433
Withdrawal symptoms, 281
Yawning, 917
YM-14673, 669
Yohimbine, 63, 353
Zimelidine, 63

AUTHOR INDEX

Abbott, B., 259
Adams, J. U., 195
Afani, A., 705
Agmo, A., 781
Ahlenius, S., 201
Akarid, K., 37
Akil, H., 673
Alex, P. K., 699
Algeri, S., 931
Ali, S. F., 861
Alkana, R. L., 639
Alleva, E., 817
Andrea, M. E., 125
Anisman, H., 69
Aprison, M. H., 191
Azcurrea, J. M., 739
Baamonde, A., 155
Babbini, M., 639
Bakshantovskaya, I. V., 315
Bao, K., 763
Baptista, T., 533
Barnes, M. I., 801
Barrett, J. E., 407
Bar-Ziv, J., 327
Becker, A., 471
Becker, H. C., 763
Beczowska, I. W., 605
Behm, F. M., 333
Belleau, B., 401
Beninger, R. J., 513
Bensimon, G., 141
Benvenga, M. J., 211
Berninsone, P. M., 739
Biegen, M. T., 681
Blick, D. W., 527
Bodnar, R. J., 605
Bosy, T. Z., 593
Bowers, B. J., 593
Bowersox, S., 1
Brase, D. A., 219
Breese, G. R., 621
Brewster, W. K., 345
Brockwell, N. T., 513
Brown, G. C., 527
Brusés, J. L., 739
Bulik, C. M., 715
Burguera, J. L., 533
Burguera, M., 533
Cada, D. A., 115
Caggiula, A. R., 715
Calcagnetti, D. J., 185
Chan, A. W. K., 433
Chang, S.-C. J. L., 853
Chaplin, R. I., 789
Chermat, R., 141
Chiarotti, F., 817
Chipkin, R. E., 21
Chodera, A., 265
Christensen, A. V., 93
Claudi, F., 131
Coffin, V. L., 21
Coghill, R. C., 475
Cohen, Y., 775
Cooley, R. K., 689
Copeland, R. L., Jr., 293, 699
Costall, B., 147, 169
Cox, M., 677
Crocker, A. D., 105
Currie, P. J., 177
Czech, D. A., 913
Damsma, G., 723
Daniel, S. S., 763
Danysz, W., 231
Darmani, N. A., 353
Davies, B. T., 905
Day, J., 723
De Boer, S. F., 13, 299
DeBold, J. F., 639
De Caro, G., 881
de Kloet, E. R., 447
Delay-Goyet, P., 155
Del Vecchio, R. A., 211
Dement, W., 1
de Saint Hilaire, Z., 545
Deutsch, S. I., 665
Dewey, W. L., 219
Diaz-Veliz, G., 705
Dilsaver, S. C., 227, 501, 695
Dohanich, G. P., 115
Dolan, S., 823
Domeney, A. M., 147, 169
Dong, L., 843
Douglass, L. W., 587
Dreher, J., 829
Drumheller, A., 463
Drummer, H. L., 235
Dulinski, J., 691
Duncan, G. E., 621
Duvauchelle, C. L., 645
Eastman, N. W., 219
Eden, R. J., 147
Ehlers, C. L., 789
Eikelboom, R., 513
Ellison, G., 927
Elmer, G. I., 897
Emerich, D. F., 875
Epstein, L. H., 715
Eshel, G., 829
Ettenberg, A., 645
Facchinetti, F., 795
Falk, J. L., 823
Farabollini, F., 795
Fassberg, J. B., 621
Feldon, J., 309
Fernández, H., 781
Fernández-Guasti, A., 371, 807
Ferrari, C. M., 267
Ferrari, F., 131
Fibiger, H. C., 723
Fink, H., 321
Finn, D. A., 639
Fischman, M. W., 417
Flemmer, D. D., 227
Foltin, R. W., 417
Fregly, M. J., 837
Frenk, H., 475
Fujimoto, K., 163
Gacel, G., 155
Gagne, M. A., 463
Garrick, N., 677
Gennaro, M., 677
Geoffroy, M., 93
George, F. R., 893, 897
Gerrard, P. A., 147, 169
Geter, B., 85
Ghosh, T. K., 293, 699
Gibbs, J., 207
Gibson, B. M., 759
Giordano, J., 49
Giroux, M. L., 695

- Gispén, W. H., 931
 Glennon, R. A., 353
 Goldberg, S. R., 411, 897
 Gomez, R. A., 125
 Gordon, C. J., 339
 Gori, E., 569
 Gorzalka, B. B., 273
 Grecksch, G., 471
 Guan, X.-M., 505
 Gunne, L., 617
- Hack, S., 281
 Hamdi, A., 215
 Handley, S. L., 63
 Hartgraves, S. L., 527
 Harvey, C. A., 147
 Hawkins, M., 1
 Heaton, J. P. W., 917
 Heinsbroek, R. P. W., 795
 Hernandez, L., 533
 Heyne, A., 389
 Hienz, R. D., 55
 Hijzen, T. H., 769
 Hillman, D. E., 685
 Hingtgen, J. N., 191
 Holtzman, S. G., 185, 195, 633
 Hong, J.-S., 801
 Hooks, M. S., 467
 Houdi, A. A., 843
 Huang, J.-T., 909
 Hudson, P. M., 801
 Hughes, R. A., 49, 247
 Huntzinger, J. A., 665
- Ikarashi, Y., 921
 Iqbal, M., 909
- Jackson, D. M., 829
 Jacquot, C., 775
 Jibiki, I., 163
 Johansson, P. E., 617
 Johnson, M. P., 135, 345
 Jolicoeur, F. B., 401, 463
 Jones, D. N. C., 169
 Jones, G. H., 467
 Jones, L. F., 601
 Josephy, M., 931
 Justice, J. B., Jr., 467
- Kalant, H., 427
 Kanarek, R. B., 681
 Katz, J. L., 411
 Kauppila, T., 287
 Kaushik, M., 665
 Kautz, M. A., 85
 Kavaliers, M., 485
 Kelly, M. E., 147
 Kelly, T. H., 417
 Kemble, E. D., 759
 Kempainen, P., 287
 Kent, S., 253
 Kerényi, S. Z., 527
 Khanna, J. M., 427
 Kimball, C. D., 909
 Koryakina, L. A., 315
 Kostrzewa, R. M., 215
 Kow, L.-M., 359, 365
 Kubota, T., 163
 Kudryavtseva, N. N., 315
 Kusanovic, R., 705
- Langán, M. C., 433
- Larsson, K., 201
 Lau, C. E., 823
 Laviola, G., 817
 Lawrence, M. S., 869
 Lee, J. D., 549
 Lee, S.-F., 549
 Leidenheimer, N. J., 99, 519
 Lemaire, S., 401
 Leong, F. W., 433
 Leshem, M., 475
 Levin, E. D., 243
 Li, D., 685
 Li, E. T. S., 495
 Li, H., 253
 Liau, L. M., 555
 Liminga, U., 617
 Lin, C.-H., 549
 Lipton, J., 927
 Liu, W.-F., 549, 747
 Loggi, G., 817
 Lorens, S. A., 223
 Luck, K. A., 273
 Luo, S., 495
 Lutfy, K., 853
- McConville, B. J., 875
 McGee, M., 501
 McKenna, D. J., 505
 McMullan, D. M., 115
 McNamara, R. K., 651
 McNaughton, N., 43
- Ma, C., 549
 Mackenzie-Taylor, D., 29
 Malatynska, E., 695
 Mangum, K. A., 115
 Markowska, A. L., 731
 Marks-Kaufman, R., 681
 Martin, B. R., 353
 Martin, W. R., 561
 Maruyama, Y., 921
 Massi, M., 881
 Massi, P., 569
 Mastropaolo, J., 665
 Matsuzaki, Y., 921
 Matthies, H., 471
 Mayer, D. J., 475
 Megirian, D., 253
 Meguro, K., 921
 Meisch, R. A., 897
 Menard, D., 401
 Mench, J. A., 587
 Middaugh, L. D., 763
 Mignot, E., 1
 Miller, D. B., 339
 Miller, S., 527
 Mintz, M., 327
 Mitchell, C. L., 801
 Mitsushio, H., 223
 Molina, V. A., 125
 Monaco, V., 889
 Mora, S., 705
 Morgat, J.-L., 155
 Morgenstern, R., 321
 Mos, J., 447
 Mundy, W. R., 861
 Muntaner, C., 411
 Murphy, M. R., 527
 Murua, V. S., 125
 Murzi, E., 533
 Myers, R. D., 379
 Myslobodsky, M. S., 327
- Nader, M. A., 611
- Nanry, K., 861
 Naylor, R. J., 147, 169
 Neill, D. B., 467
 Nichols, D. E., 135, 345, 581
 Nicholson, D., 753
 Nicolaïdis, S., 545
 Njung'e, K., 63
 Noda, Y., 441
 Norman, A. B., 875
 Novitzki, M. R., 665
 Nowak, G., 691
 Nowakowska, E., 265
 Nyce, J. W., 379
- Oberlender, R., 135, 581
 O'Callaghan, J. P., 339
 Ochi, Y., 441
 O'Connor, D. A., 267
 O'Connor, S., 1
 Ojea, S. I., 739
 Oka, M., 441
 Olivier, B., 447
 Olson, K. G., 219
 Ong, J., 829
 Orosco, M., 775
 Ott, T., 321
 Overstreet, D. H., 105
 Owen, D. A. A., 147
- Paez, X., 379
 Pandey, U., 353
 Papanek, P. E., 837
 Parenti, M., 569
 Paris, J. M., 223
 Park, W. K., 191
 Parker, L. A., 375
 Parolaro, D., 569
 Patrini, G., 569
 Paul, I. A., 621
 Paule, M. G., 77
 Peck, J. A., 227, 501
 Penetrante, M. L., 433
 Perfumi, M., 881
 Perkins, K. A., 715
 Peroutka, S. J., 555
 Perretta, G., 889
 Pertovaara, A., 287
 Pfaff, D. W., 359, 365
 Pitha, J., 555
 Pitsikas, N., 931
 Polidori, C., 881
 Pompei, P. L., 881
 Pournaghash, S., 479
 Powell, K. R., 621
 Pradhan, S. N., 293, 699
 Pruitt, T., 561
- Radulovacki, M., 1
 Ramsey, V. A., 659
 Rawleigh, J. M., 759
 Rech, R. H., 29
 Redmond, E., Jr., 869
 Reeber, C., 837
 Reid, A., 753
 Reite, M., 677
 Rijnders, H. J., 769
 Riley, A. L., 85, 267, 479
 Ríos, C., 807
 Rivest, R., 401, 463
 Robert, J. J., 775
 Rodefer, J., 715
 Rogers, B. C., 861
- Roques, B. P., 155, 545
 Rose, J. E., 243, 333
 Rosenberg, H. C., 659
 Rouch, C., 775
 Rubino, T., 569
 Ruethrich, H.-L., 471
 Ruiz-Gayo, M., 155
- Saldívar, A., 371, 807
 Samson, H. H., 575
 Sanberg, P. R., 875
 Sasaki, H., 921
 Satinoff, E., 253
 Sawynok, J., 753
 Schanley, D. L., 433
 Schechter, M. D., 7, 99, 519, 539
 Schino, G., 889
 Schipper, J., 447
 Schneider, R., 471
 Schnur, P., 711
 Schou, J. S., 93
 Schulze, G. E., 77
 Sekizawa, K., 921
 Shah, G., 427
 Shanks, N., 69
 Shea, M. M., 587
 Shechtman, O., 837
 Shih, J.-H., 549
 Shimada, E., 441
 Shofel, A., 309
 Shreve, P. E., 385
 Shulgin, A. T., 505
 Sierra, V., 853
 Sijbesma, H., 447
 Simansky, K. J., 459
 Skelton, R. W., 651
 Slangen, J. L., 13, 299, 769
 Sleight, A. J., 555
 Sloan, J. W., 561
 Smith, A. D., 467
 Smith, G. P., 207
 Spear, D. J., 411
 Spruijt, B. M., 931
 Starr, B. S., 259
 Starr, M. S., 259
 Steele, T. D., 345
 St-Pierre, S., 463
 Stumpf, W. E., 621
 Sufka, K. J., 49, 247
 Sutton, D., 909
 Syapin, P. J., 639
- Tackett, R. L., 601
 Takishima, T., 921
 Tanco, S. A., 273
 Tandon, P., 861
 Tang, M., 823
 Tapia, C., 705
 Tarrasch, R., 327
 Teskey, G. C., 485
 Tesserommatis, C., 813
 Tietz, E. I., 659
 Tilson, H. A., 861
 Tolliver, G. A., 575
 Tomkowiak, J. M., 253
 Touzani, K., 37
 Tripathi, H. L., 219
 Tripp, G., 43
 Troisi, A., 889
 Trujillo, K. A., 673
 Tsopanakis, C., 813
 Turkkan, J. S., 55

Turndorf, H., 685
Tvede, K., 93
Tyers, M. B., 169
Tyrka, A., 207

Uretsky, N. J., 385

van Aken, H., 447
van Bergen, P., 837
Van De Poll, N. E., 795
Van Der Gugten, J., 13, 299
Vanderwolf, C. H., 689
Vander Zanden, J. M., 913

Van Loon, G. R., 843
Varrin, S. J., 917
Velley, L., 37

Wala, E. P., 561
Wall, T. L., 789
Wang, B. C., 685
Watkinson, W. P., 339
Wehner, J. M., 593
Weiner, I., 309
Weiner, J., 427
Wellman, P. J., 905
Wenk, G. L., 731

West, R., 281
Wetherington, C. L., 85
White, E. S., 681
Wilkins, J., 927
Wilson, L. M., 177
Wing, A. V., 211
Winter, E., 109
Wolffgramm, J., 389
Wong, L. S., 829
Woolley, D. E., 235
Wright, A., 147

Yamaguchi, N., 163

Yamamoto, M., 669, 921
Yanai, M., 921
Yatsugi, S., 669
Yim, G. K. W., 345
Yoburn, B. C., 853
Young, C. W., 633

Zacharko, R. M., 69
Zalcman, S., 69
Zanol, M. D., 875
Zeigler, S., 927
Zhang, L., 407